<DOC>
	<DOCNO>NCT01643941</DOCNO>
	<brief_summary>This Phase 1 Phase 2 study single vaccination one three dose level 4-antigen investigational vaccine Staphylococcus aureus ( SA4Ag ) single dose level 3-antigen Staphylococcus aureus vaccine ( SA3Ag ) . The main goal study determine safe well tolerate vaccine well describe immune response elicit vaccine healthy adult age 65 &lt; 86 year . In addition , study aim assess effect Staphylococcus aureus vaccine presence Staphylococcus aureus within nose , throat perineal skin healthy adult age 65 &lt; 86 year .</brief_summary>
	<brief_title>Evaluation Single Vaccination One Three Ascending Dose Levels 4-Antigen Staphylococcus Aureus Vaccine ( SA4Ag ) Single Dose Level 3-Antigen Staphylococcus Aureus Vaccine ( SA3Ag ) Healthy Adults Aged 65 &lt; 86 Years</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male healthy postmenopausal female , age 65 &lt; 86 year enrollment , determine medical history , physical examination , clinical judgment investigator eligible study . Subjects preexist chronic medical condition determine stable may include . Available entire duration study , able comply schedule visit , study plan , laboratory test , study procedure include completion electronic diary ( e diary ) Day 1 Day 14 follow vaccination . Able contact telephone study participation . Male subject , opinion investigator , biologically capable father child , sexually active woman childbearing potential must agree use highly effective method contraception throughout study . Unstable chronic medical condition disease require significant change therapy hospitalization worsen disease within 3 month receipt study vaccine . Serious chronic medical disorder disorder investigator 's opinion precludes subject participate study . Donation blood volume 250 mL great donation plasma within 3 month prior enrollment conclusion study . Bleeding condition associate prolonged bleeding time may contraindicate intramuscular injection blood draw include subject take anticoagulant , antiplatelet and/or antithrombotic agent except lowdose daily aspirin within 30 day enrollment completion Visit 6 ( Day 29 ) . Any contraindication vaccination vaccine component , include previous anaphylactic reaction vaccine vaccine related component . Immunocompromised person subject currently immunosuppressive therapy history immunosuppressive therapy . History immunemodifying drug . Previous administration S. aureus vaccination . Any infection proven suspect caused S. aureus within 6 month precede study vaccination . Receipt blood product immunoglobulin ( include monoclonal antibody ) within 12 month enrollment conclusion study . Participation investigational interventional study within 30 day current study begin and/or study participation . Participation purely observational study acceptable . Subjects investigational site staff member subject immediate family member ( firstdegree relative ) investigational site staff member Pfizer employee directly involve conduct trial . Residence nursing home longterm care facility requirement semiskilled nursing care . An ambulatory subject resident retirement home village eligible trial . A MiniMental State Examination ( MMSE ) score â‰¤21 . For Phase 1 subject , abnormality screen hematology , coagulation , and/or blood chemistry laboratory value except note protocol Subjects know active disease human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , and/or hepatitis C virus ( HCV ) , Phase 1 subject positive screen test HIV , HBV and/or HCV . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Planned surgical procedure within 30 day follow vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Staphylococcus aureus</keyword>
	<keyword>vaccine</keyword>
	<keyword>Staphylococcal infection</keyword>
</DOC>